Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
[HTML][HTML] Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma
Background In a pilot study involving patients with cutaneous squamous-cell carcinoma, a
high percentage of patients had a pathological complete response with the use of two doses …
high percentage of patients had a pathological complete response with the use of two doses …
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3 …
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
[HTML][HTML] Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma
To define the cellular composition and architecture of cutaneous squamous cell carcinoma
(cSCC), we combined single-cell RNA sequencing with spatial transcriptomics and …
(cSCC), we combined single-cell RNA sequencing with spatial transcriptomics and …
Targeting cancer stem cell pathways for cancer therapy
L Yang, P Shi, G Zhao, J Xu, W Peng, J Zhang… - Signal transduction and …, 2020 - nature.com
Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …